Abstract
The rapid evolving knowledge of glioblastoma molecular biomarkers and their association to prognosis and treatment calls for clinicians to keep abreast of the latest literature on the recommendations that have an impact on clinical practice. The presence or absence of IDH mutations and MGMT methylation continue to be essential molecular markers that indicate prognosis and response to treatment. New emerging data on the presence of other alterations such as TERT promoter mutation, EGFR amplification, and/or the combination of gain of entire chromosome 7 and loss of entire chromosome 10 (+7/−10) in the case of IDH-wildtype astrocytomas and the presence of CDKN2A/B in IDH-mutant astrocytomas have become significant as these mutations are associated with more aggressive tumor behavior. Other mutations such as EGFRvIII expression, FGFR-TACC gene fusions, PTEN deletion, PDGFRA and BRAF V 600E have elucidated important pathways for targeted therapies and aid in prognosis assessment.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
van den Bent MJ, et al. A clinical perspective on the 2016 WHO brain tumor classification and routine molecular diagnostics. Neuro-Oncology. 2017;19(5):614–24.
Louis DN, et al. cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading. Brain Pathol. 2020;30(4):844–56.
Louis DN, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803–20.
Louis DN, et al. Announcing cIMPACT-NOW: the consortium to inform molecular and practical approaches to CNS tumor taxonomy. Acta Neuropathol. 2017;133(1):1–3.
Louis DN, et al. cIMPACT-NOW (the consortium to inform molecular and practical approaches to CNS tumor taxonomy): a new initiative in advancing nervous system tumor classification. Brain Pathol. 2017;27(6):851–2.
Zhang C, et al. IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma. Neuro-Oncology. 2013;15(9):1114–26.
Parsons DW, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321(5897):1807–12.
Romanidou O, Kotoula V, Fountzilas G. Bridging cancer biology with the clinic: comprehending and exploiting IDH gene mutations in gliomas. Cancer Genomics Proteomics. 2018;15(5):421–36.
Miyata S, et al. Comprehensive metabolomic analysis of IDH1R132H clinical glioma samples reveals suppression of β-oxidation due to carnitine deficiency. Sci Rep. 2019;9(1):9787.
Clark O, Yen K, Mellinghoff IK. Molecular pathways: isocitrate dehydrogenase mutations in cancer. Clin Cancer Res. 2016;22(8):1837–42.
Hartmann C, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol. 2009;118(4):469–74.
Dang L, Yen K, Attar EC. IDH mutations in cancer and progress toward development of targeted therapeutics. Ann Oncol. 2016;27(4):599–608.
Ohgaki H, Kleihues P. The definition of primary and secondary glioblastoma. Clin Cancer Res. 2013;19(4):764.
Waitkus MS, Diplas BH, Yan H. Isocitrate dehydrogenase mutations in gliomas. Neuro-Oncology. 2016;18(1):16–26.
Jalbert LE, et al. Metabolic profiling of IDH mutation and malignant progression in infiltrating glioma. Sci Rep. 2017;7:44792.
Ostrom QT, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012–2016. Neuro-Oncology. 2019;21(Suppl_5):v1–v100.
Yan H, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8):765–73.
Molinaro AM, et al. Genetic and molecular epidemiology of adult diffuse glioma. Nat Rev Neurol. 2019;15(7):405–17.
Christians A, et al. The prognostic role of IDH mutations in homogeneously treated patients with anaplastic astrocytomas and glioblastomas. Acta Neuropathol Commun. 2019;7(1):156.
Tejera D, et al. Ivosidenib, an IDH1 inhibitor, in a patient with recurrent, IDH1-mutant glioblastoma: a case report from a phase I study. CNS Oncol. 2020;9:Cns62.
Mellinghoff, I. K., et al. Ivosidenib in Isocitrate Dehydrogenase 1-Mutated Advanced Glioma. J Clin Oncol 2020;38(29):3398–406.
De La Fuente MI, et al. A phase Ib/II study of olutasidenib in patients with relapsed/refractory IDH1 mutant gliomas: safety and efficacy as single agent and in combination with azacitidine. J Clin Oncol. 2020;38(15_Suppl):2505.
Galanis E, et al. Integrating genomics into neuro-oncology clinical trials and practice. Am Soc Clin Oncol Educ Book. 2018;38:148–57.
Popovici-Muller J, et al. Discovery of AG-120 (Ivosidenib): a first-in-class mutant IDH1 inhibitor for the treatment of IDH1 mutant cancers. ACS Med Chem Lett. 2018;9(4):300–5.
Brat DJ, et al. cIMPACT-NOW update 3: recommended diagnostic criteria for “diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV”. Acta Neuropathol. 2018;136(5):805–10.
Tesileanu CMS, et al. Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria. Neuro-Oncology. 2019;22(4):515–23.
Stupp R, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459–66.
Binabaj MM, et al. The prognostic value of MGMT promoter methylation in glioblastoma: a meta-analysis of clinical trials. J Cell Physiol. 2018;233(1):378–86.
Yu W, et al. O(6)-methylguanine-DNA methyltransferase (MGMT): challenges and new opportunities in glioma chemotherapy. Front Oncol. 2020;9:1547.
Mansouri A, et al. MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges. Neuro-Oncology. 2019;21(2):167–78.
Dahlrot RH, et al. Posttreatment effect of MGMT methylation level on glioblastoma survival. J Neuropathol Exp Neurol. 2019;78(7):633–40.
Brigliadori G, et al. Defining the cutoff value of MGMT gene promoter methylation and its predictive capacity in glioblastoma. J Neuro-Oncol. 2016;128(2):333–9.
Hegi ME, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997–1003.
Estival A, et al. Pyrosequencing versus methylation-specific PCR for assessment of MGMT methylation in tumor and blood samples of glioblastoma patients. Sci Rep. 2019;9(1):11125.
Hsu C-Y, et al. Prognosis of glioblastoma with faint MGMT methylation-specific PCR product. J Neuro-Oncol. 2015;122(1):179–88.
Pinson H, et al. Weak MGMT gene promoter methylation confers a clinically significant survival benefit in patients with newly diagnosed glioblastoma: a retrospective cohort study. J Neuro-Oncol. 2020;146(1):55–62.
Malmström A, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol. 2012;13(9):916–26.
Kalra B, Kannan S, Gupta T. Optimal adjuvant therapy in elderly glioblastoma: results from a systematic review and network meta-analysis. J Neuro-Oncol. 2020;146(2):311–20.
Wee CW, et al. Chemoradiation in elderly patients with glioblastoma from the multi-institutional GBM-molRPA cohort: is short-course radiotherapy enough or is it a matter of selection? J Neuro-Oncol. 2020;148(1):57–65.
Hanna C, et al. Treatment of newly diagnosed glioblastoma in the elderly: a network meta-analysis. Cochrane Database Syst Rev. 2020;3(3):Cd013261.
Perry JR, et al. Short-course radiation plus temozolomide in elderly patients with glioblastoma. N Engl J Med. 2017;376(11):1027–37.
Zhou M, et al. The value of MGMT promote methylation and IDH-1 mutation on diagnosis of pseudoprogression in patients with high-grade glioma: a meta-analysis. Medicine. 2019;98(50):e18194.
Brandes AA, et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol. 2008;26(13):2192–7.
Wen PY, et al. Response assessment in neuro-oncology clinical trials. J Clin Oncol Off J Am Soc Clin Oncol. 2017;35(21):2439–49.
Thust SC, van den Bent MJ, Smits M. Pseudoprogression of brain tumors. J Magn Reson Imaging. 2018;48(3):571–89.
Chukwueke UN, Wen PY. Use of the response assessment in neuro-oncology (RANO) criteria in clinical trials and clinical practice. CNS Oncol. 2019;8(1):CNS28.
Maire CL, Ligon KL. Molecular pathologic diagnosis of epidermal growth factor receptor. Neuro-Oncology. 2014;16 Suppl 8(Suppl 8):viii1–6.
Cimino PJ, et al. A wide spectrum of EGFR mutations in glioblastoma is detected by a single clinical oncology targeted next-generation sequencing panel. Exp Mol Pathol. 2015;98(3):568–73.
Brennan CW, et al. The somatic genomic landscape of glioblastoma. Cell. 2013;155(2):462–77.
An Z, et al. Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies. Oncogene. 2018;37(12):1561–75.
Mellinghoff IK, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med. 2005;353(19):2012–24.
Aldape K, et al. Glioblastoma: pathology, molecular mechanisms and markers. Acta Neuropathol. 2015;129(6):829–48.
Neftel C, et al. An integrative model of cellular states, plasticity, and genetics for glioblastoma. Cell. 2019;178(4):835–849.e21.
Kessler T, et al. Molecular profiling-based decision for targeted therapies in IDH wild-type glioblastoma. Neurooncol Adv. 2020;2(1):vdz060.
Brito C, et al. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation. BMC Cancer. 2019;19(1):968.
Alexandru O, et al. Receptor tyrosine kinase targeting in glioblastoma: performance, limitations and future approaches. Contemp Oncol (Pozn). 2020;24(1):55–66.
Weller M, et al. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncol. 2017;18(10):1373–85.
Milella M, et al. PTEN: multiple functions in human malignant tumors. Front Oncol. 2015;5:24.
Han F, et al. PTEN gene mutations correlate to poor prognosis in glioma patients: a meta-analysis. Onco Targets Ther. 2016;9:3485–92.
Yang J-M, et al. Characterization of PTEN mutations in brain cancer reveals that pten mono-ubiquitination promotes protein stability and nuclear localization. Oncogene. 2017;36(26):3673–85.
Rosenthal M, et al. Buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma: a phase Ib/II, open-label, multicentre, randomised study. ESMO Open. 2020;5(4):e000672.
Wen PY, et al. Phase I, open-label, multicentre study of buparlisib in combination with temozolomide or with concomitant radiation therapy and temozolomide in patients with newly diagnosed glioblastoma. ESMO Open. 2020;5(4):e000673.
Maraka S, Janku F. BRAF alterations in primary brain tumors. Discov Med. 2018;26(141):51–60.
Bond CE, Whitehall VLJ. How the BRAF V600E mutation defines a distinct subgroup of colorectal cancer: molecular and clinical implications. Gastroenterol Res Pract. 2018;2018:9250757.
Kushnirsky M, et al. Prolonged complete response with combined dabrafenib and trametinib after BRAF inhibitor failure in BRAF-mutant glioblastoma. JCO Precis Oncol. 2020;4:44–50.
Ida CM, et al. Pleomorphic xanthoastrocytoma: natural history and long-term follow-up. Brain Pathol. 2015;25(5):575–86.
Dias-Santagata D, et al. BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications. PLoS One. 2011;6(3):e17948.
Koelsche C, et al. Mutant BRAF V600E protein in ganglioglioma is predominantly expressed by neuronal tumor cells. Acta Neuropathol. 2013;125(6):891–900.
Phadnis S, et al. Rare-20. BRAF mutations in pediatric gangliogliomas and the clinical significance an MD Anderson Cancer Center experience. Neuro-Oncology. 2018;20(Suppl_6):vi240.
Korshunov A, et al. Epithelioid glioblastomas stratify into established diagnostic subsets upon integrated molecular analysis. Brain Pathol. 2018;28(5):656–62.
Behling F, et al. Frequency of BRAF V600E mutations in 969 central nervous system neoplasms. Diagn Pathol. 2016;11(1):55.
Zeng Y, et al. Clinicopathological, immunohistochemical and molecular genetic study on epithelioid glioblastoma: a series of fifteen cases with literature review. Onco Targets Ther. 2020;13:3943–52.
Kanemaru Y, et al. Dramatic response of BRAF V600E-mutant epithelioid glioblastoma to combination therapy with BRAF and MEK inhibitor: establishment and xenograft of a cell line to predict clinical efficacy. Acta Neuropathol Commun. 2019;7(1):119.
Burger MC, et al. Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease. Oncol Rep. 2017;38(6):3291–6.
Lassman A, et al. OS10.6 Infigratinib (BGJ398) in patients with recurrent gliomas with fibroblast growth factor receptor (FGFR) alterations: a multicenter phase II study. Neuro-Oncology. 2019;21:iii21–2.
Meric-Bernstam F, et al. Abstract CT238: TAS-120 in patients with advanced solid tumors bearing FGF/FGFR aberrations: a phase I study. Cancer Res. 2019;79(13 Supplement):CT238.
Zhang R-Q, et al. Biomarker-based prognostic stratification of young adult glioblastoma. Oncotarget. 2016;7(4):5030–41.
Lassman AB, et al. Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627). Neuro-Oncology. 2015;17(7):992–8.
Galanis E, et al. A phase 1 and randomized, placebo-controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872. Cancer. 2019;125(21):3790–800.
Jiao Y, Feng Y, Wang X. Regulation of tumor suppressor gene CDKN2A and encoded p16-INK4a protein by covalent modifications. Biochem Mosc. 2018;83(11):1289–98.
Lu VM, et al. The prognostic significance of CDKN2A homozygous deletion in IDH-mutant lower-grade glioma and glioblastoma: a systematic review of the contemporary literature. J Neuro-Oncol. 2020;148(2):221–9.
Brat DJ, et al. cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. Acta Neuropathol. 2020;139(3):603–8.
Yang RR, et al. IDH mutant lower grade (WHO Grades II/III) astrocytomas can be stratified for risk by CDKN2A, CDK4 and PDGFRA copy number alterations. Brain Pathol. 2020;30(3):541–53.
Appay R, et al. CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas. Neuro-Oncology. 2019;21:1519–28.
Mirchia K, et al. Total copy number variation as a prognostic factor in adult astrocytoma subtypes. Acta Neuropathol Commun. 2019;7(1):92.
Reis GF, et al. CDKN2A loss is associated with shortened overall survival in lower-grade (World Health Organization Grades II–III) astrocytomas. J Neuropathol Exp Neurol. 2015;74(5):442–52.
Patel B, et al. TERT, a promoter of CNS malignancies. Neurooncol Adv. 2020;2(1):vdaa025.
Yuan X, Larsson C, Xu D. Mechanisms underlying the activation of TERT transcription and telomerase activity in human cancer: old actors and new players. Oncogene. 2019;38(34):6172–83.
Killela PJ, et al. Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas. Oncotarget. 2014;5(6):1515–25.
Bollam SR, Berens ME, Dhruv HD. When the ends are really the beginnings: targeting telomerase for treatment of GBM. Curr Neurol Neurosci Rep. 2018;18(4):15.
Lee Y, et al. The frequency and prognostic effect of TERT promoter mutation in diffuse gliomas. Acta Neuropathol Commun. 2017;5(1):62.
Reifenberger G, et al. Advances in the molecular genetics of gliomas — implications for classification and therapy. Nat Rev Clin Oncol. 2017;14(7):434–52.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
del Pilar Guillermo Prieto, M., de La Fuente, M.I. (2021). The Role of Molecular Genetics of Glioblastoma in the Clinical Setting. In: Otero, J.J., Becker, A.P. (eds) Precision Molecular Pathology of Glioblastoma. Molecular Pathology Library. Springer, Cham. https://doi.org/10.1007/978-3-030-69170-7_2
Download citation
DOI: https://doi.org/10.1007/978-3-030-69170-7_2
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-69169-1
Online ISBN: 978-3-030-69170-7
eBook Packages: MedicineMedicine (R0)